Which one is better, dasatinib or nilotinib?

Evaluating the cost-effectiveness of second-line nilotinib and dasatinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia chronic phase (Ph+ CML-CP) who are resistant or intolerant to imatinib from a U.S. third-party perspective.

Methods:A lifetime split survival model was developed to compare the cost and effectiveness of niblotinib and dasatinib, which included four health states: CPon treatment, CP pan>After drug withdrawal, progressive disease(accelerated phase[AP] or blast phase[BC])and death. Duration to treatment, progression-free survival, and overall survival of nilotinib and dasatinib were assessed using real-world comparative effectiveness data. Parametric survival models were used to extrapolate outcomes beyond the study period. Medication costs, medical costs, and adverse event costs were obtained from the literature and publicly available databases. Health state utility was derived from the literature. Incremental cost-effectiveness ratios, including incremental cost per life-year gained (LY) and incremental cost per quality-adjusted life-year (QALY) gained, were evaluated by comparing nilotinib with dasatinib. Deterministic sensitivity analysis was performed by varying patient characteristics, cost, and utility inputs.

Results:Over the lifetime, patients treated with nilotinib experienced 11.7 LYs and 9.1 QALYs, the total cost was 1, 409, 466USD, compared with 9.5 for patients treated with dasatinib. LYs, 7.3 QALYs, total cost was 1, 422, 122 USD. Compared with dasatinib, nilotinib has better health outcomes(2.2 LYs vs. 1.9 QALYs)and lower total costs(12, 655USD). Deterministic sensitivity analysis results show that the results are consistent in most cases.

Limitations:Lifetime predictions cannot be verified in the absence of long-term real data.

Conclusion:Among patients with Ph+ CML-CP who are resistant or intolerant to imatinib, second-line lotinib is associated with better life expectancy, better quality of life, and lower costs compared with dasatinib. There are generic drugs overseas, produced in India and Bangladesh, and each box costs about four to five hundred. For specific prices, you can consult domestic regular overseas pharmaceutical consulting agencies. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0